Structure Encountered

Scribe Therapeutics

Develops CRISPR-based genetic medicines using engineered Cas proteins for cardiometabolic diseases.

Scribe disclosed three preclinical cardiometabolic programs at ASGCT, running both epigenetic silencing and CasX editing in parallel.

SIGNAL·Preclinical platform disclosure·3 preclinical programs·SCORE 80·19 MAY 2026 · 12:47 UTC

● CAPTURE — IMAGE INCOMINGFRAME 01 / 01

Structure Scribe Therapeutics, captured by Voyager

STRUCT. / SCRIBE THERAPEUTICS

/ Alameda, California, United States

CAPT. / 19.05.26 12:47:05Z

SIGNAL / 80 / 100

Image relayed by The Biotech Voyager during pass over structure Scribe Therapeutics. Resolution as transmitted.

001Vital Statistics

DATA LOCKED

Designation

Scribe Therapeutics

Coordinates

Alameda, California, United States

Stage

Preclinical

Type

Therapeutics

Modalities

CRISPR · gene therapy · epigenetic editing · AI/ML

Therapeutic area

Cardiovascular · Metabolic

002Signature Detected

EVENT DETECTED

Event type

Preclinical platform disclosure

Magnitude

3 preclinical programs

Lead

Scribe Therapeutics

Participating

Presented at ASGCT 2026

003Architecture

PLATFORM PROFILE

Target class

Lipid-pathway genes: PCSK9 for LDL, LPA for Lp(a), and a triglyceride regulator. Targeted via either epigenetic silencing or CasX editing, in vivo, hepatocyte-directed.

Differentiator

Verve edits the DNA at PCSK9. Scribe's STX-1150 leaves DNA alone and silences the gene epigenetically via the ELXR platform, theoretically reversible. STX-1200 and STX-1400 are CasX edits at Lp(a) and triglycerides. Three shots on the cardiometabolic goal, two mechanisms.

Lead asset

STX-1150 (LDL, ELXR epigenetic silencer), preclinical, IND filing planned summer 2026

Pipeline depth

3 disclosed cardiometabolic: STX-1150 (LDL/ELXR), STX-1200 (Lp(a)/XE), STX-1400 (triglycerides/XE). Plus Lilly CNS collab and Sanofi cardiometabolic collab.

004Voyager Assessment

MACHINE-GENERATED

Scribe has been the quiet sibling in CRISPR cardiometabolics while Verve has taken all the press. ASGCT changed that. Three disclosed programs, two mechanisms, one tissue. STX-1150 is the epigenetic silencer headed to IND this summer, no permanent DNA edit. STX-1200 and STX-1400 are CasX edits at Lp(a) and triglycerides. Doudna's company is now running both the reversible and permanent versions of cardiometabolic gene control in parallel, with Lilly and Sanofi already paying for the platform. That's two thesis bets, not one.

005Adjacent Structures

FRONTIER MAP

Verve Therapeutics· in vivo base editing, cardiometabolicMetagenomi Therapeutics, Inc.· in vivo CRISPR, metabolicEpigenic Therapeutics· epigenetic silencing, ShanghaiAccurEdit Therapeutics· in vivo CRISPR via LNPIonis Pharmaceuticals· PCSK9, Lp(a) ASO incumbentEli Lilly· $1.5B Scribe CNS partnerSanofi· $1.2B Scribe cardiometabolic partner

— End of transmission —This signal was received and processed by The Biotech Voyager and HOUSTON. Transmissions are auto-generated from public sources and platform telemetry. They are not edited for prose. For human analysis and connection to other signals, watch the Tuesday or Thursday mission broadcast aboard the [SHIP]. Field notes — long-form synthesis from the crew — are archived separately.